Pharmacological profile of ramosetron, a novel therapeutic agent for IBS

@article{Hirata2006PharmacologicalPO,
  title={Pharmacological profile of ramosetron, a novel therapeutic agent for IBS},
  author={T. Hirata and T. Funatsu and Y. Keto and M. Nakata and M. Sasamata},
  journal={Inflammopharmacology},
  year={2006},
  volume={15},
  pages={5-9}
}
  • T. Hirata, T. Funatsu, +2 authors M. Sasamata
  • Published 2006
  • Medicine
  • Inflammopharmacology
    • Abstract.Ramosetron is a potent and selective serotonin (5-HT)3 receptor antagonist that has been shown to affect abnormal colonic function and abdominal pain in animals. Ramosetron (0.3 to 100 µg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide. On the other hand… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    25 Citations
    Highly Influencial Citations
    1
    Background Citations
    8
    25 Citations
    Citation Type

    Citation Type

    Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.
    • 13
    Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
    • 26
    • Highly Influenced
    • PDF
    Effects of serotonin 5‐HT3 receptor antagonists on stress‐induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer
    • T. Hirata, Y. Keto, +5 authors K. Miyata
    • Medicine
    • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
    • 2008
    • 46
    Emerging Pharmacologic Therapies for Irritable Bowel Syndrome
    • 18
    A Phase II Trial of the Novel Serotonin Type 3 Receptor Antagonist Ramosetron in Japanese Male and Female Patients with Diarrhea-Predominant Irritable Bowel Syndrome
    • 75
    Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome
    • 43
    Serotonin and GI clinical disorders
    • 184
    Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    • 15
    Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient‐controlled analgesia in breast cancer patients
    • 23
    Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome
    • M. Camilleri
    • Medicine
    • Clinical pharmacology and therapeutics
    • 2012
    • 42

    References

    SHOWING 1-10 OF 53 REFERENCES
    Role of the serotonin3 receptor in stress-induced defecation.
    • 107
    Involvement of the 5-HT3 receptor in CRH-induce defecation in rats.
    • 59
    Involvement of the 5-HT3 receptor in CRH-induced defecation in rats.
    • 16
    • PDF
    5-Hydroxytryptamine3 receptor antagonism modulates a noxious visceral pseudoaffective reflex
    • 24
    Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice
    • 30
    Intracolonic glycerol induces abdominal contractions in rats: Role of 5‐HT3 receptors
    • 19
    CRF1 receptor signaling pathways are involved in stress‐related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome
    • 211
    Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells.
    • 30
    A 5-HT3 receptor agonist induces neurally mediated chloride transport in rat distal colon.
    • 32
    The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinalc-fos expression in the anaesthetised rat
    • 144
    • PDF